An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7-Day Triple Therapy With Bismuth Versus 14-Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents.

ABSTRACT:

Background

To achieve eradication rates > 90%, the ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori infection recommend tailored antimicrobial therapy using sufficiently high doses over 10-14 days. However, prolonged treatment often leads to suboptimal compliance in children, which is a major contributor to reduced eradication rates. To address this, we evaluated the efficacy and safety of a shorter, 7 day triple therapy with bismuth compared with the 14 day standard triple therapy without bismuth in H. pylori infected children.

Materials and methods

From 2020 to 2024, we carried out a randomized controlled trial involving treatment-naïve children and adolescents (5-18 years old) with confirmed H. pylori infection. Eligible participants were randomly allocated t

SUBMITTER: Sterbenc A 

PROVIDER: S-EPMC12776654 | biostudies-literature | 2026 Jan-Feb

REPOSITORIES: biostudies-literature